Search | Clinical Trials Finder

Conditions: Cardiovascular Risk Factor
Interventions: No to Low Endogenous Estrogen, Estradiol; Other
Lead sponsor: University of Delaware; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions: Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream; Drug
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older · Female only
Enrollment: 111 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Castration-Sensitive Prostate Adenocarcinoma, Metastatic Castration-Sensitive Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Interventions: Androgen Receptor Pathway Inhibitor, Transdermal Estrogen, Bone Scan, Computed Tomography, Dual X-ray Absorptiometry, Gonadotropin-releasing Hormone Analog, Magnetic Resonance Imaging, Survey Administration, Biospecimen Collection; Drug · Procedure · Biological + 1 more
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older · Male only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Breast Cancer
Interventions: Fulvestrant, Tamoxifen; Drug
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years and older · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 3
States / cities: New York, New York

Conditions: Advanced Breast Cancer, Metastatic Breast Cancer, Breast Cancer, Breast Carcinoma, Cancer of the Breast, Cancer of Breast, Malignant Tumor of Breast, Breast Tumor
Interventions: NUV-422, Fulvestrant; Drug
Lead sponsor: Nuvation Bio Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 5
States / cities: Anaheim, California • Fountain Valley, California • Canton, Ohio + 2 more

Conditions: Obesity
Interventions: leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training; Drug · Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 79 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2014
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer
Interventions: TTI-101, Palbociclib, Aromatase inhibitor (AI), fulvestrant, ribociclib; Drug
Lead sponsor: Tvardi Therapeutics, Incorporated; Industry
Eligibility: 18 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 6
States / cities: Fort Lauderdale, Florida • St Louis, Missouri • Nashville, Tennessee + 2 more

Conditions: Advanced Breast Cancer
Interventions: ARV-471, Fulvestrant; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 624 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 87
States / cities: Encinitas, California • Fountain Valley, California • Fresno, California + 69 more

Conditions: Healthy Volunteers
Interventions: Leuprolide Acetate 3.75, Estradiol, Progesterone, Placebo suppository, Placebo patch; Drug
Lead sponsor: National Institute of Mental Health (NIMH); NIH
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1994 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Menopause, Postmenopause
Interventions: Estrogen; Drug
Lead sponsor: National Center for Research Resources (NCRR); NIH
Eligibility: 35 Years to 75 Years · Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Menopausal Syndrome
Interventions: Estradiol (E2), Progesterone (P10) x90, Progesterone (P10) x10; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 45 Years to 55 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Metastatic Breast Cancer
Interventions: Palbociclib + an aromatase inhibitor, Aromatase inhibitor; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 2,888 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Mammographic Density, Abnormal Mammogram
Interventions: CEE pill, Estradiol patch, Active Progesterone, Placebo tablet, Placebo patch, Placebo progesterone; Drug · Other
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 42 Years to 58 Years · Female only
Enrollment: 517 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Adhesive Capsulitis of the Shoulder, Frozen Shoulder
Interventions: Hormone Replacement Therapy (HRT), Corticosteroid and 1%lidocain, physical therapy; Drug · Behavioral
Lead sponsor: University of California, San Francisco; Other
Eligibility: 40 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: ER-Positive HER2-Negative Breast Cancer
Interventions: AZD9833, Anastrozole, Anastrozole placebo, AZD9833 placebo, Palbociclib, Luteinizing hormone-releasing hormone (LHRH) agonist; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 130 Years
Enrollment: 1,370 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 30
States / cities: Mobile, Alabama • Springdale, Arkansas • Harbor City, California + 25 more

Conditions: Breast Cancer, Solid Tumors, Adult
Interventions: STX-478, Fulvestrant, Ribociclib, Palbociclib, Letrozole, Anastrozole, Exemestane, Tamoxifen, Abemaciclib, Imlunestrant, Metformin; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 880 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 28
States / cities: Los Angeles, California • San Francisco, California • Aurora, Colorado + 22 more

Conditions: Menopause, Postmenopause, Premenopause, Cardiovascular Disease
Interventions: transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium); Drug
Lead sponsor: Northwestern University; Other
Eligibility: 47 Years to 55 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1998 – 2005
U.S. locations: 2
States / cities: Chicago, Illinois • Seattle, Washington

Conditions: Alzheimer Disease
Interventions: Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 55 Years to 90 Years · Female only
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Atherosclerosis, Healthy, Vascular Disease
Interventions: Estradiol, Progesterone; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Female only
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Healthy
Interventions: Fulvestrant; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 50 Years to 80 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Perimenopausal Disorder, Depression
Interventions: Bazedoxifene/Conjugated Estrogen; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 44 Years to 55 Years · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metastatic Breast Cancer
Interventions: Seribantumab, Fulvestrant, Placebo; Drug
Lead sponsor: Elevation Oncology; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Chandler, Arizona • Fayetteville, Arkansas • Beverly Hills, California + 19 more

Conditions: Breast Cancer
Interventions: Vagifem; Behavioral
Lead sponsor: Susan Tannenbaum; Other
Eligibility: 18 Years and older · Female only
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Farmington, Connecticut

Conditions: Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions: exemestane, adjuvant therapy, aromatase inhibition, conventional surgery, endocrine therapy, hormone therapy, neoadjuvant therapy, surgery; Drug · Procedure
Lead sponsor: Robert H. Lurie Cancer Center; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Chicago, Illinois

Search by objective public record fields.

Menopause Effects on Vascular Function

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

Estrogen to Improve Quality of Life for Men With Newly Diagnosed or Recurrent Metastatic Hormone Sensitive Prostate Cancer, EQUIP Trial

Examination of Breast Cancer Cells of Pre-menopausal and Post-menopausal Women Before and After Exposure to Tamoxifen or Fulvestrant.

Study of NUV-422 in Combination With Fulvestrant in Patients With HR+HER2- aBC

Prevention of Obesity in Women Via Estradiol Regulation

Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast Cancer

A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer

The Effects of Reproductive Hormones on Mood and Behavior

Buccal Estrogen in Toothpaste Study: Systemic Absorption of Estradiol When Administered Mixed With Toothpaste in Postmenopausal or Surgically Menopausal Women

Early Menopause Hormone Treatment and Cognition

Real-World Effectiveness of Palbociclib in Combination With an Aromatase Inhibitor

KEEPS Mammographic Density And Breast Health Ancillary Study

Frozen Shoulder and Hormone Replacement Therapy

A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease

First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

Midlife Cholesterol Study

Alzheimer's Disease: Therapeutic Potential of Estrogen

Effects of Hormone Replacement Therapy on Inflammation and Stiffening of Artery Walls

Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women

Effects of a Tissue Selective Estrogen Complex (TSEC) on Depression and the Neural Reward System in the Perimenopause"

Phase 2 Trial of Seribantumab Plus Fulvestrant in Postmenopausal Women With Metastatic Breast Cancer

Trial of Vaginal Estrogen for Urogenital Symptom Relief in Women on Aromatase Inhibitors

Neoadjuvant and Adjuvant Exemestane in Treating Postmenopausal Women With Locally Advanced Hormone Receptor-Positive Breast Cancer